423 related articles for article (PubMed ID: 19451436)
1. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Maki RG; D'Adamo DR; Keohan ML; Saulle M; Schuetze SM; Undevia SD; Livingston MB; Cooney MM; Hensley ML; Mita MM; Takimoto CH; Kraft AS; Elias AD; Brockstein B; Blachère NE; Edgar MA; Schwartz LH; Qin LX; Antonescu CR; Schwartz GK
J Clin Oncol; 2009 Jul; 27(19):3133-40. PubMed ID: 19451436
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Ray-Coquard I; Italiano A; Bompas E; Le Cesne A; Robin YM; Chevreau C; Bay JO; Bousquet G; Piperno-Neumann S; Isambert N; Lemaitre L; Fournier C; Gauthier E; Collard O; Cupissol D; Clisant S; Blay JY; Penel N;
Oncologist; 2012; 17(2):260-6. PubMed ID: 22285963
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of sorafenib in metastatic thyroid cancer.
Kloos RT; Ringel MD; Knopp MV; Hall NC; King M; Stevens R; Liang J; Wakely PE; Vasko VV; Saji M; Rittenberry J; Wei L; Arbogast D; Collamore M; Wright JJ; Grever M; Shah MH
J Clin Oncol; 2009 Apr; 27(10):1675-84. PubMed ID: 19255327
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
von Mehren M; Rankin C; Goldblum JR; Demetri GD; Bramwell V; Ryan CW; Borden E
Cancer; 2012 Feb; 118(3):770-6. PubMed ID: 21751200
[TBL] [Abstract][Full Text] [Related]
5. A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Dahut WL; Scripture C; Posadas E; Jain L; Gulley JL; Arlen PM; Wright JJ; Yu Y; Cao L; Steinberg SM; Aragon-Ching JB; Venitz J; Jones E; Chen CC; Figg WD
Clin Cancer Res; 2008 Jan; 14(1):209-14. PubMed ID: 18172272
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
Nabors LB; Supko JG; Rosenfeld M; Chamberlain M; Phuphanich S; Batchelor T; Desideri S; Ye X; Wright J; Gujar S; Grossman SA;
Neuro Oncol; 2011 Dec; 13(12):1324-30. PubMed ID: 21954442
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
Williamson SK; Moon J; Huang CH; Guaglianone PP; LeBlanc M; Wolf GT; Urba SG
J Clin Oncol; 2010 Jul; 28(20):3330-5. PubMed ID: 20498388
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
Grignani G; Palmerini E; Dileo P; Asaftei SD; D'Ambrosio L; Pignochino Y; Mercuri M; Picci P; Fagioli F; Casali PG; Ferrari S; Aglietta M
Ann Oncol; 2012 Feb; 23(2):508-16. PubMed ID: 21527590
[TBL] [Abstract][Full Text] [Related]
9. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Matei D; Sill MW; Lankes HA; DeGeest K; Bristow RE; Mutch D; Yamada SD; Cohn D; Calvert V; Farley J; Petricoin EF; Birrer MJ
J Clin Oncol; 2011 Jan; 29(1):69-75. PubMed ID: 21098323
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
Moreno-Aspitia A; Morton RF; Hillman DW; Lingle WL; Rowland KM; Wiesenfeld M; Flynn PJ; Fitch TR; Perez EA
J Clin Oncol; 2009 Jan; 27(1):11-5. PubMed ID: 19047293
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS; Oza AM; Morgan RJ; Huo D; Elit L; Knost JA; Wade JL; Agamah E; Vokes EE; Fleming GF
Gynecol Oncol; 2010 Apr; 117(1):37-40. PubMed ID: 20117828
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
Sridhar SS; Winquist E; Eisen A; Hotte SJ; McWhirter E; Tannock IF; Mukherjee SD; Wang L; Blattler C; Wright JJ; Moore MJ
Invest New Drugs; 2011 Oct; 29(5):1045-9. PubMed ID: 20191303
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Pacey S; Ratain MJ; Flaherty KT; Kaye SB; Cupit L; Rowinsky EK; Xia C; O'Dwyer PJ; Judson IR
Invest New Drugs; 2011 Jun; 29(3):481-8. PubMed ID: 20016927
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
Gitlitz BJ; Moon J; Glisson BS; Reimers HJ; Bury MJ; Floyd JD; Schulz TK; Sundaram PK; Ho C; Gandara DR
J Thorac Oncol; 2010 Nov; 5(11):1835-40. PubMed ID: 20881645
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Bodnar L; Górnas M; Szczylik C
Gynecol Oncol; 2011 Oct; 123(1):33-6. PubMed ID: 21723597
[TBL] [Abstract][Full Text] [Related]
17. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
Raut CP; Boucher Y; Duda DG; Morgan JA; Quek R; Ancukiewicz M; Lahdenranta J; Eder JP; Demetri GD; Jain RK
PLoS One; 2012; 7(2):e26331. PubMed ID: 22347360
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
19. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
20. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Aragon-Ching JB; Jain L; Gulley JL; Arlen PM; Wright JJ; Steinberg SM; Draper D; Venitz J; Jones E; Chen CC; Figg WD; Dahut WL
BJU Int; 2009 Jun; 103(12):1636-40. PubMed ID: 19154507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
